Jagsonpal Pharmaceuticals Ltd approves Q2/H1 FY27 results, with standalone Q2 revenue of ₹813.75 million
- Standalone Q2 revenue rose 9.3% year on year and fell 1.0% sequentially.
- Consolidated Q2 net profit was ₹122.87 million; no comparative periods were presented, following the acquisition of Aequitas Healthcare.
- Results include ₹2.35 million in exceptional acquisition-related professional fees; auditors issued unmodified limited-review conclusions.